Decreased Hospital Length of Stay With Early Administration of Oseltamivir in Patients Hospitalized With Influenza
- PMID: 32280928
- PMCID: PMC7139986
- DOI: 10.1016/j.mayocpiqo.2019.12.005
Decreased Hospital Length of Stay With Early Administration of Oseltamivir in Patients Hospitalized With Influenza
Abstract
Objective: To evaluate the effects of timely oseltamivir administration in patients hospitalized with seasonal influenza.
Patients and methods: We performed a single-center retrospective cohort study for hospitalized patients who tested positive for influenza between December 1, 2010, and July 1, 2014. We compared outcomes for patients who received antivirals within 48 hours of symptoms to those of patients who either received oseltamivir after 48 hours or never received oseltamivir. Hospital length of stay (LOS) and 90-day mortality were compared using Cox regression models. Antiviral administration was analyzed as a time-varying covariate.
Results: During the study period, 433 patients were hospitalized with laboratory-confirmed influenza. Of these patients, 146 (33.7%) received oseltamivir within 48 hours of symptoms, 202 (46.7%) received oseltamivir after 48 hours of symptoms, and 85 (19.6%) did not receive antivirals. Baseline characteristics were similar among these patient groups. Receiving oseltamivir within 48 hours was associated with shorter hospital LOS (5.9 days vs 7.2 days; P=.03) but no significant difference in 90-day mortality (13.7% vs 11.5%; P=.51). In a Cox regression analysis, patients who received antivirals within 48 hours had a 50% higher chance of being discharged (hazard ratio, 1.50; 95% CI, 1.14-1.98) on any given day during hospital stay.
Conclusion: In patients hospitalized with laboratory-confirmed influenza, timely administration of oseltamivir was associated with shorter hospital LOS.
Keywords: HR, hazard ratio; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; NAI, neuraminidase inhibitor; PCR, polymerase chain reaction.
© 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.
Figures

References
-
- Fiore A.E., Fry A., Shay D., Gubareva L., Bresee J.S., Uyeki T.M. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2011;60(1):1–24. - PubMed
-
- Thompson W.W., Shay D.K., Weintraub E., et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–1340. - PubMed
-
- Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–5096. - PubMed
-
- World Health Organization Influenza (seasonal) [fact sheet]. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs211/en/ Published November 6, 2018. Accessed July 11, 2019.
-
- Centers for Disease Control and Prevention (CDC) Estimates of deaths associated with seasonal influenza—United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057–1062. - PubMed
LinkOut - more resources
Full Text Sources